Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. - Wikidata - awgldk - TriplyDB

Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.

Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.

http://www.wikidata.org/entity/Q38395012

about

Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis.Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients.The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss

P2860

Q28073952-61523B9B-ED00-4620-9C8F-AB486CA8B4ED Q33746277-3F33E579-B6BA-4D0A-9885-A9846EDE16BB Q38520997-CBF96C4D-6A84-4DAC-AE1C-27EA0D8B612D Q38563981-ADAC288B-DC78-431F-BE03-70763A9477D9 Q38817050-99952E06-2A16-49B6-8A73-4A3B9A969A6E Q38996589-0376C8DA-FB47-4B3E-8A86-CFC16F393449 Q48242279-917F789F-2C6F-4871-BE1C-3335F5587D0A Q58728851-0DEFE28E-4855-4816-A8FE-1B109A7423FC

P2860

Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.

http://www.wikidata.org/entity/Q38395012

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Changes in the endocannabinoid ...... y in TDP-43-related disorders.

@en

type

label

Changes in the endocannabinoid ...... y in TDP-43-related disorders.

@en

prefLabel

Changes in the endocannabinoid ...... y in TDP-43-related disorders.

@en

P1433

Q38395012-B6BF64D6-98A3-4A8D-9D52-FEFC41669324

P1476

Q38395012-DFF1C289-D7CC-4F44-9920-E2662D0724FE

P2093

Q38395012-244CA894-092D-4C4F-A586-32C624E2A349

Q38395012-2E6515EA-75D4-4797-BE3B-E17BE2239083

Q38395012-B72D3957-8F7F-44FD-99EA-5145A6BF58C2

P2860

Q38395012-0730AEFE-F2AF-418E-A3FF-4471037939A8

Q38395012-0C6ED659-924F-4006-BD8D-B78EBCDC836B

Q38395012-12E732D7-C25C-4C04-ADC1-A74001958B68

Q38395012-165F2BA0-A39E-47A9-9F8F-AE8E02B9D389

Q38395012-2029473D-0EE4-46A5-BC12-0E9AA20F3DC6

Q38395012-20CD7829-19A5-4A72-8926-46A157A64273

Q38395012-2A3DFA17-F8A6-4AAA-9A39-25C453A4B76A

Q38395012-2D179756-DEB8-46BB-9C00-E7D98BED413A

Q38395012-336A2B33-CA28-4377-A24B-04957FE8220D

Q38395012-3F746E18-8EF8-4364-91E6-231BDA6B037C

P2888

Q38395012-AD057514-F3B6-4180-ABE0-0F0C4C6061B6

P304

Q38395012-6EDED5CB-2775-4A4B-9447-6484D61E7E1F

P31

Q38395012-B1B42970-67B6-4E0B-ADE5-38610ED71F50

P356

Q38395012-71C572D7-8885-4B52-ABE5-70387BCEF19C

P433

Q38395012-4D8D3F0C-C757-4C8C-9455-614D6ED2510D

P478

Q38395012-6B58275B-A6D7-432E-8CA6-6DE7B2330B2D

P50

Q38395012-080E6D78-5C8A-43A2-9ABF-D1333263D01E

Q38395012-362BB712-B6AC-4CBD-8968-56620864CB33

Q38395012-7E31EACA-AFCD-4E95-AB33-C0F3C150961F

Q38395012-FC3F59A4-F960-4146-A4EF-B410C290CA3D

P577

Q38395012-D8CF506D-2D84-42E1-8F96-36864926D915

P6179

Q38395012-B6896D57-FA1D-4568-830A-644D943651EC

P698

Q38395012-7CA95B2A-1C9A-4FF6-91EC-78AF400CB8E0

P921

Q38395012-D5DAEB32-9382-486A-8A53-0C8444449559

P356

S11481-015-9602-4

P1433

Journal of Neuroimmune Pharmacology

P1476

Changes in the endocannabinoid ...... y in TDP-43-related disorders.

@en

P2093

Javier Fernández-Ruiz

http://www.w3.org/2001/XMLSchema#string

José A Ramos

http://www.w3.org/2001/XMLSchema#string

Roberta Verde

http://www.w3.org/2001/XMLSchema#string

P2860

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders

State of play in amyotrophic lateral sclerosis genetics

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.

Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.

CB2: a cannabinoid receptor with an identity crisis

The epidemiology of ALS: a conspiracy of genes, environment and time.

P2888

s11481-015-9602-4

P304

233-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11481-015-9602-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Vincenzo Di Marzo

Fabiana Piscitelli

Francisco Espejo-Porras

P577

2015-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036316701

http://www.w3.org/2001/XMLSchema#string

P698

25819934

http://www.w3.org/2001/XMLSchema#string

P921

endocannabinoid system